Skip to main content

Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma

Objective

The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans.
We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma

Field of science

  • /natural sciences/biological sciences/microbiology/virology
  • /natural sciences/biological sciences/ecology
  • /natural sciences/biological sciences/microbiology/bacteriology
  • /medical and health sciences/basic medicine/physiology/pathophysiology
  • /medical and health sciences/clinical medicine/pneumology/asthma
  • /medical and health sciences/clinical medicine/allergology

Call for proposal

H2020-FETOPEN-1-2016-2017
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Address
6 Christou Lada Str
10561 Athina
Greece
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 353 750

Participants (9)

THE UNIVERSITY OF MANCHESTER
United Kingdom
EU contribution
€ 1 128 000
Address
Oxford Road
M13 9PL Manchester
Activity type
Higher or Secondary Education Establishments
SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
Switzerland
EU contribution
€ 287 500
Address
Promenade 35
7270 Davos Platz
Activity type
Research Organisations
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 222 500
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
UNIVERSYTET MEDYCZNY W LODZI.
Poland
EU contribution
€ 232 500
Address
Al. Kosciuszki, 4
90419 Lodz
Activity type
Higher or Secondary Education Establishments
UMEA UNIVERSITET
Sweden
EU contribution
€ 217 500
Address
Universitetomradet
901 87 Umea
Activity type
Higher or Secondary Education Establishments
GIORGI ELIAVA INSTITUTE OF BACTERIOPHAGY, MICROBIOLOGY AND VIROLOGY
Georgia
EU contribution
€ 222 500
Address
Gotua Street 3
0160 Tbilisi
Activity type
Other
ELIAVA BIO PREPARATIONS LTD
Georgia
EU contribution
€ 60 000
Address
Gotua Street 3
0160 Tbilisi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING
Belgium
EU contribution
€ 112 500
Address
Rue Du Congrès 35
1000 Brussels
Activity type
Other
MARIOS LYMARAKIS KAI SIA EE
Greece
EU contribution
€ 135 000
Address
Ethnikis Antistaseos 132
15344 Gerakas Attiki
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)